Life-threatening invasive meningococcal disease requires prompt treatment. Of those who get it 10-20% get severe organ and tissue damage and can require life-long care; while 10-15% who get it die.

Our evidence review concludes that the MenB, Bexsero® vaccine will provide signficant direct protection for those most at risk. It can be given as part of other routine vaccinations for infants and children, along with prophylactic paracetemol. Vaccination is also recommended for adolescents and young adults at increased risk of meningococcal disease due to life-style factors.

DOI number

Menu category

Research, Diseases, Vaccines

Authors

Immunisation Advisory Centre

Publication

Type of research

Literature review

Last updated:
Jan 2023